A pilot study on the effect of acetyl-L-carnitine in paclitaxel-and cisplatin-induced peripheral neuropathy

Tumori

Volumn 91, Issue 2, 2005, Pages 135-138

  Maestri, Antonio ^a   De Pasquale Ceratti, Adolfo ^b   Cundari, Sante ^c   Zanna, Claudio ^c   Cortesi, Enrico ^b   Crinò, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

Acetyl L carnitine; Chemotherapy induced peripheral neuropathy; Ciplatin; Paclitaxel

Indexed keywords

CISPLATIN; LEVACECARNINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; PERIPHERAL NEUROPATHY; WORLD HEALTH ORGANIZATION;

EID: 18944404875     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100206     Document Type: Article

References (25)

1. Hilkens PH, ven den Bent MJ: Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst, 2: 350-361, 1997.
2. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol, 249: 9-17, 2002.
3. Forman A: Peripheral neuropathy in cancer patients: incidence, features, and pathophysiology. Oncology (Huntingt), 4: 57-62, 1990.
4. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol, 35: 305-311, 1994.
5. Almadrones LA, Arcot R: Patient guide to peripheral neuropathy. Oncol Nurs Forum, 26: 1359-1360, 1999.
6. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L: Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16: 153-158, 1998.
7. Electrodiagnostic parameters in the assesment of paclitaxel neuropathy. Proc ASCO; 16: 258A, 1997.
8. Warner E: Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer, 5: 161-169, 1995.
9. Kedar A, Cohen ME, Freeman AL: Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report. Cancer Treat Rep, 62: 819-821, 1978.
10. Hadley D, Herr HW: Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment. Cancer, 44: 2026-2028, 1979.
11. Cowan JD, Kies MS, Roth JL, Joice RP: Nerve conduction studies in patients treated with cis-dichlorodiammineplatinum (II): a preliminary report. Cancer Treat Report, 64: 1119-1122, 1980.
12. Ashraf M, Scotchel PL, Krall JM, Flink EB: Cis-platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol, 16: 309-318, 1983.
13. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res, 9: 5756-5767, 2003.
14. De Grandis D, Minardi C: Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D, 3: 223-231, 2002.
15. Montgomery SA, Thal LJ, Amrein R: Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol, 18: 61-71, 2003.
16. WHO Handbook for reporting results of cancer treatment, WHO Offset Publication 1979, no. 48, Geneva.
17. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res, 7: 1192-1197, 2001.
18. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G: neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 20: 3478-3483, 2002.
19. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Congetti F, Bove L: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol, 21: 927-931, 2003.
20. Cavaletti G, Zanna C: Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer, 38: 1832-1837, 2002.
21. Vitali G, Ravaglia S, Bianchi G: Symptomatic and neurophysiological response of paclitaxel and/or cisplatin neuropathy to oral acetyl-L-carnitine (ALCAR). Ann Oncol, 13 (Suppl 5): 659P, 2002.
22. Ernst E, Resch KL: Concept of true and perceived placebo effect. Br Med J, 311: 551-553, 1995.
23. Hanauske AR, Schilling T, Heinrich B: Clinical phase 1 study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin Oncol, 22: 35-39, 1995.
24. Grunberg SM, Sonka S, Stevenson LL, Muggia FM: Progressive paraesthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol, 25: 62-64, 1989.
25. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C: Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology, 61: 1297-1300, 2003.